TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.0750nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.140nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.150nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.160nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.170nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.170nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.170nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.170nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.180nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.260nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.310nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.310nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.360nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.370nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.370nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.400nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.540nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.910nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 1.20nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 2.80nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 3.30nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 4.80nMAssay Description:Table 10: IC50 values for the inhibition of FLT3 kinase enzymatic activity by midostaurin, HSN286, 334 and 356 were determined. All of the four compo...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 5.60nMAssay Description:Table 10: IC50 values for the inhibition of FLT3 kinase enzymatic activity by midostaurin, HSN286, 334 and 356 were determined. All of the four compo...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 6.30nMAssay Description:This cell-based assay measures the ability of compounds to inhibit forskolin stimulated cAMP in CHO-K1 cells overexpressing SSTR4. CHO-K1 cells overe...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 6.70nMAssay Description:Table 8: The binding of HSN286, HSN336, HSN334, HSN248 and HSN247 with several FLT3 secondary mutations (Table 8) was investigated. Interestingly, HS...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 6.70nMAssay Description:Table 10: IC50 values for the inhibition of FLT3 kinase enzymatic activity by midostaurin, HSN286, 334 and 356 were determined. All of the four compo...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 7nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 7.90nMAssay Description:Table 10: IC50 values for the inhibition of FLT3 kinase enzymatic activity by midostaurin, HSN286, 334 and 356 were determined. All of the four compo...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 19nMAssay Description:Table 8: The binding of HSN286, HSN336, HSN334, HSN248 and HSN247 with several FLT3 secondary mutations (Table 8) was investigated. Interestingly, HS...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 19nMAssay Description:Table 10: IC50 values for the inhibition of FLT3 kinase enzymatic activity by midostaurin, HSN286, 334 and 356 were determined. All of the four compo...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 26nMAssay Description:Table 10: IC50 values for the inhibition of FLT3 kinase enzymatic activity by midostaurin, HSN286, 334 and 356 were determined. All of the four compo...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 27.6nMAssay Description:Table 8: The binding of HSN286, HSN336, HSN334, HSN248 and HSN247 with several FLT3 secondary mutations (Table 8) was investigated. Interestingly, HS...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 330nMAssay Description:Table 10: IC50 values for the inhibition of FLT3 kinase enzymatic activity by midostaurin, HSN286, 334 and 356 were determined. All of the four compo...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 330nMAssay Description:Table 8: The binding of HSN286, HSN336, HSN334, HSN248 and HSN247 with several FLT3 secondary mutations (Table 8) was investigated. Interestingly, HS...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 450nMAssay Description:Table 8: The binding of HSN286, HSN336, HSN334, HSN248 and HSN247 with several FLT3 secondary mutations (Table 8) was investigated. Interestingly, HS...More data for this Ligand-Target Pair
